Literature DB >> 29366936

Functional attribution of LdISP, an endogenous serine protease inhibitor from Leishmania donovani in promoting infection.

Md Nur Alam1, Sajal Chakraborti1, Dibyendu Paik1, Angshuman Bagchi1, Tapati Chakraborti2.   

Abstract

Leishmaniasis, a parasitic disease caused by unicellular eukaryotic protozoa of the genus Leishmania, affects more than 12 million people worldwide. Events of leishmaniasis are based on the infection of the mammalian host, precisely macrophages, where both host and parasite derived proteases and endogenous inhibitors are significant. Pathogen derived protease inhibitors have generated considerable interest as they often act as an agent promoting infection and parasitic survivability. An endogenous serine protease inhibitor from Indian strain of Leishmania donovani was previously identified by our group and named as LdISP. It has been found to inhibit neutrophil elastase (NE), responsible for natural inflammation process. However, LdISP's role in progression of infection or the proteomics based structural exposition has not been explored. The present study is aimed to localize and validate the potential role of LdISP in infectivity. We found that LdISP localized endogenously and treatment of infected host cells with LdISP curbs ROS and NO production. Additionally, in silico studies are carried out to predict the putative amino acid residues of LdISP involved in the inhibition process. Taken together, our results demonstrate that LdISP eventually exerts a pronounced role in L. donovani infection.
Copyright © 2018 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Human neutrophil elastase; Inhibitor; LdISP; Leishmania; Macrophage; Serine protease

Mesh:

Substances:

Year:  2018        PMID: 29366936     DOI: 10.1016/j.biochi.2018.01.005

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  2 in total

1.  Neutrophil elastase promotes Leishmania donovani infection via interferon-β.

Authors:  Bruna T Dias; Karina Luisa Dias-Teixeira; Joseane P Godinho; Marilia S Faria; Teresa Calegari-Silva; Maowia M Mukhtar; Ulisses Lopes; Jeremy C Mottram; Ana Paula C A Lima
Journal:  FASEB J       Date:  2019-07-05       Impact factor: 5.191

2.  Discovery of Leishmania Druggable Serine Proteases by Activity-Based Protein Profiling.

Authors:  Exequiel O J Porta; Jaime A Isern; Karunakaran Kalesh; Patrick G Steel
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.